KinCon biolabs has secured new funding from the Austrian Research Promotion Agency (FFG) to launch “Seek & Destroy,” an R&D project applying KinCon’s patented live-cell reporter platform to the fast-growing, still-emerging field of targeted protein degradation (TPD). The goal: illuminate previously “undruggable” targets implicated in cancer and Parkinson’s disease and accelerate drug discovery.
KinCon’s genetically encoded reporters visualize conformational changes and drug binding inside living cells, delivering direct readouts of target engagement, efficacy, and selectivity. The expansion of KinCon biolabs’ platform supports the design of new degraders and has already been validated in pilot studies with a leading pharmaceutical company, underscoring the impact of the approach.
